<h2 dir="ltr"><strong>Atopic Dermatitis</strong></h2>
<p dir="ltr"><a href="https://www.delveinsight.com/report-store/atopic-dermatitis-ad-market"><strong>Atopic Dermatitis</strong></a> is a chronic inflammatory skin disorder characterized by recurrent itching, redness, dryness, and skin barrier dysfunction that can occur at any age and often persists throughout life.</p>
<h3 dir="ltr"><strong>Atopic Dermatitis Epidemiology Segmentation</strong></h3>
<ul>
<li dir="ltr" role="presentation">Total Prevalent Cases of Atopic Dermatitis</li>
<li dir="ltr" role="presentation">Total Diagnosed Cases of Atopic Dermatitis</li>
<li dir="ltr" role="presentation">Age-specific Diagnosed Cases of Atopic Dermatitis</li>
<li dir="ltr" role="presentation">Severity-specific Diagnosed Cases of Atopic Dermatitis</li>
<li dir="ltr" role="presentation">Gender-specific Diagnosed Cases of Atopic Dermatitis</li>
</ul>
<h2 dir="ltr"><strong>Atopic Dermatitis Epidemiology</strong></h2>
<ul>
<li dir="ltr" role="presentation">The total diagnosed prevalent cases of Atopic Dermatitis in the 7MM were estimated at approximately 53 million in 2025.</li>
<li dir="ltr" role="presentation">In 2025, the United States accounted for nearly 45% of diagnosed prevalent cases, while EU4 and the UK represented approximately 42%, followed by Japan with nearly 13% of cases.</li>
<li dir="ltr" role="presentation">The increasing incidence of atopic dermatitis in younger populations, combined with limited approved treatment options for pediatric patients, is expected to drive demand for safer and more effective long-term therapies.</li>
<li dir="ltr" role="presentation">Advancements in biologics, targeted immunotherapies, and greater awareness regarding chronic inflammatory skin diseases are contributing to rising diagnosis and treatment adoption rates across the 7MM.</li>
</ul>
<h2 dir="ltr"><strong>Atopic Dermatitis Market</strong></h2>
<ul>
<li dir="ltr" role="presentation">The Atopic Dermatitis market size in the 7MM was estimated at approximately USD 13 billion in 2025.</li>
<li dir="ltr" role="presentation">In 2025, nearly 69% of the total market share was occupied by the United States.</li>
<li dir="ltr" role="presentation">Among all therapies for Atopic Dermatitis, DUPIXENT generated the highest revenue in the United States in 2025.</li>
<li dir="ltr" role="presentation">The Atopic Dermatitis market is evolving rapidly as treatment approaches shift from broad-spectrum biologics toward targeted therapies, including JAK inhibitors and IL-targeted agents, owing to their favorable efficacy, safety, and expanded pediatric indications.</li>
<li dir="ltr" role="presentation">Current treatment strategies include topical therapies such as emollients, topical corticosteroids, topical calcineurin inhibitors, and systemic therapies including immunosuppressants, corticosteroids, biologics, and phototherapy.</li>
</ul>
<h3 dir="ltr"><strong>Atopic Dermatitis Market Drivers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Rising prevalence of Atopic Dermatitis is significantly increasing demand for effective treatment options.</li>
<li dir="ltr" role="presentation">Growing opportunities in pediatric and long-term maintenance therapies are supporting market expansion.</li>
<li dir="ltr" role="presentation">The evolving competitive landscape with emerging biologics and targeted therapies is accelerating innovation.</li>
<li dir="ltr" role="presentation">Increasing healthcare expenditure and improved patient access to advanced dermatology treatments are driving market growth.</li>
</ul>
<h3 dir="ltr"><strong>Atopic Dermatitis Market Barriers</strong></h3>
<ul>
<li dir="ltr" role="presentation">There is currently no definitive cure for Atopic Dermatitis, and treatment primarily focuses on symptom management and inflammation control.</li>
<li dir="ltr" role="presentation">Lack of personalized and age-specific therapies continues to create challenges in long-term disease management.</li>
<li dir="ltr" role="presentation">Patent expirations of blockbuster therapies such as DUPIXENT may increase biosimilar competition and impact market share.</li>
<li dir="ltr" role="presentation">Variability in patient response and absence of standardized diagnostic guidelines may limit optimal treatment selection.</li>
</ul>
<h3 dir="ltr"><strong>Emerging Atopic Dermatitis Drugs</strong></h3>
<ul>
<li dir="ltr" role="presentation">Rocatinlimab (KHK4083/AMG451)</li>
<li dir="ltr" role="presentation">Amlitelimab (KY1005)</li>
<li dir="ltr" role="presentation">Orismilast</li>
<li dir="ltr" role="presentation">Bosakitug (BSI-045B)</li>
<li dir="ltr" role="presentation">Afimkibart (RG6631)</li>
<li dir="ltr" role="presentation">And others</li>
</ul>
<h3 dir="ltr"><strong>Key Atopic Dermatitis Companies</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">LEO Pharma</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Roche</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Eli Lilly and Company</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">AbbVie</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Pfizer</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Sanofi</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Regeneron Pharmaceuticals</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Kyowa Kirin</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Amgen</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">UNION Therapeutics</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Aclaris Therapeutics</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Biosion</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Genentech</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">And others</p>
</li>
</ul>
<p class="ql-align-justify">&nbsp;</p>

Atopic Dermatitis (AD) Infographics

Atopic Dermatitis (AD) Market

Atopic Dermatitis (AD), Atopic Dermatitis (AD) Market, Atopic Dermatitis (AD) Infographics, Atopic Dermatitis Pipeline